Clonality of multifocal nonsmall cell lung cancer: Implications for staging and therapy

European Respiratory Journal

Volumn 39, Issue 6, 2012, Pages 1437-1442

  Warth, Arne ^a   Macher Goeppinger, Stephan ^a,b   Muley, Thomas ^c   Thomas, Michael ^d   Hoffmann, Hans ^d   Schnabel, Philipp A ^a   Penzel, Roland ^a   Schirmacher, Peter ^a   Aulmann, Sebastian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Translational Research Unit   (Germany)

^d Dept of Thoracic Oncology ^*  (Germany)

Author keywords

Adenocarcinoma; Clinical lung cancer; Loss of heterozygosity analysis; Lung cancer chemotherapy; Lung cancer diagnosis; Thoracic oncology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLONAL VARIATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EVIDENCE BASED PRACTICE; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTIPLE CANCER; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT DECISION MAKING; PRIMARY TUMOR; PRIORITY JOURNAL; RECEPTOR GENE; SHORT TANDEM REPEAT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861872352     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00105911     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol 2010; 7: 401-414.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
4. Gazdar AF, Minna JD. Multifocal lung cancers-clonality vs field cancerization and does it matter? J Natl Cancer Inst 2009; 101: 541-543.
5. Mathisen DJ, Jensik RJ, Faber LP, et al. Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg 1984; 88: 502-510.
6. Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst 2009; 101: 560-570.
7. Ferguson MK, DeMeester TR, DesLauriers J, et al. Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg 1985; 89: 378-385.
8. Vansteenkiste JF, De Belie B, Deneffe GJ, et al. Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up. Lung Cancer 2001; 34: 169-175.
9. Asamura H. Multiple primary cancers or multiple metastases, that is the question. J Thorac Oncol 2010; 5: 930-931.
10. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975; 70: 606-612.
11. Antakli T, Schaefer RF, Rutherford JE, et al. Second primary lung cancer. Ann Thorac Surg 1995; 59: 863-866.
12. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
13. Shen KR, Meyers BF, Larner JM, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edn). Chest 2007; 132: 290S-305S.
14. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary non-small cell carcinomas from metastases. Am J Surg Pathol 2009; 33: 1752-1764.
15. World Health Organization. Classification of Tumors. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
16. Aulmann S, Schleibaum J, Penzel R, et al. Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status. J Clin Pathol 2008; 61: 1034-1037.
17. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small- cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857-865.
18. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-968.
19. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract-its etiology, manifestation, and significance. J Otolaryngol 1984; 13: 1-6.
20. Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009; 15: 5184-5190.
21. Shimizu S, Yatabe Y, Koshikawa T, et al. High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res 2000; 6: 3994-3999.
22. Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009; 4: 809-815.
23. Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 2006; 119: 1491-1494.
24. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99: 923-929.
25. Italiano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 2006; 17: 981-985.
26. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009; 20: 696-702.
27. Gomez-Roca C, Raynaud CM, Penault-Llorca F, et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 2009.
28. Daniele L, Cassoni P, Bacillo E, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol 2009; 4: 684-688.
29. Cortot AB, Italiano A, Burel-Vandenbos F, et al. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010; 116: 2682-2687.
30. Badalian G, Barbai T, Raso E, et al. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res 2007; 13: 99-104.